- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03748745
A Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects
August 12, 2019 updated by: Nanjing Sanhome Pharmaceutical, Co., Ltd.
A Single-center, Open-label, Steady-state Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects
The purpose of this study is to evaluate the drug-drug interaction of SH229 tablets and Daclatasvir dihydrochloride tablets.
The study also evaluates the pharmacokinetics and tolerability of co-administration of SH229 tablets and Daclatasvir dihydrochloride tablets in healthy subjects.
This study provides evidence for the designing of following clinical trial protocols.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A total of 28 evaluable healthy subjects will be enrolled in this study.
The dose of SH229 is 600 mg.
The dose of Daclatasvir dihydrochloride is 60 mg.
Study Type
Interventional
Enrollment (Actual)
28
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jilin
-
Changchun, Jilin, China, 130000
- Phase I Clinical Trial Unit, The First Hospital of Jilin University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Sign the informed consent form before the study and fully understand the study content, process and possible adverse reactions;
- Be able to complete the study as required by the protocol;
- Subjects (including their partners) who are willing to voluntarily take effective contraceptive measures from screening to 6 months after the last dose. See the appendix for specific contraceptive measures;
- Male subjects aged 18-45 (including 18 and 45 years old);
- Male subjects who weigh no less than 50 kg and have a body mass index between 18 and 28 kg / m2 (including the threshold). Body mass index (BMI) = weight (kg) / height2 (m2);
- Physical examination and vital signs normal, or the abnormal signs have no clinical significance.
Exclusion Criteria:
- Smoke more than 5 cigarettes per day within three months prior to study;
- Subjects who are allergic to the study drugs or prone to allergies (Multiple drug and food allergies);
- Subjects with history of drug and/or alcohol abuse (14 units per week: 1 unit = 285 mL of beer, or 25 mL of hard liquor, or 100 mL of wine);
- Subjects with history of blood donation or massive blood loss (> 450 mL) within three months prior to screening;
- Subjects with dysphagia or have history of gastrointestinal disorders which affects study drug absorption;
- Subjects with any diseases that increase the risk of bleeding, such as hemorrhoids, acute gastritis, or gastric and duodenal ulcers;
- Use of any drugs that alter liver enzyme activity within 28 days prior to screening;
- Use of any prescription drugs, over-the-counter drugs, vitamin products or herbal medicines within 14 days prior to screening;
- Use of special diet (including dragon fruit, mango, grapefruit, etc.), strenuous activities or other factors that may affect the absorption, distribution, metabolism and excretion of the study drug within 2 weeks prior to screening;
- Concomitant use of strong inhibitors or inducers of CYP3A4, P-gp or Bcrp, such as itraconazole, ketoconazole or dronedarone;
- Subjects with major changes in diet or exercise habits recently;
- Use of study drugs or participation in other clinical trials within three months prior to dosing;
- Subjects who have ECG abnormalities with clinical significance;
- Subjects who have abnormalities with clinical significant in clinical laboratory tests or other clinical findings that indicate clinically significant diseases (including but not limited to gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric or cardiovascular diseases);
- Subjects with viral hepatitis (including hepatitis B and hepatitis C), AIDS antibody and/or antibody screening positive for Treponema pallidum;
- Subjects with acute disease or concomitant use of drugs from screening stage to dosing;
- Use of chocolate, food or beverages containing caffeine or xanthine within 24 hours prior to dosing;
- Use of products containing alcohol within 24 hours prior to dosing;
- Subjects with urine drug screening test positive, or with history of drug abuse in the past 5 years;
- Subjects with any other reasons that investigator considers to be unsuitable for the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A
SH229 (600 mg) once daily, Daclatasvir dihydrochloride (60 mg) once daily.
|
tablet, oral, 600 mg once daily for day 1 to day 14
tablet, oral, 600 mg once daily for day 8 to day 14
tablet, oral, 60 mg once daily for day 8 to day 14
tablet, oral, 60 mg once daily for day 1 to day 14
|
Experimental: Cohort B
SH229 (600 mg) once daily, Daclatasvir dihydrochloride (60 mg) once daily.
|
tablet, oral, 600 mg once daily for day 1 to day 14
tablet, oral, 600 mg once daily for day 8 to day 14
tablet, oral, 60 mg once daily for day 8 to day 14
tablet, oral, 60 mg once daily for day 1 to day 14
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: Up to 1 month after last dose
|
Cohort A and Cohort B [Safety and tolerability]
|
Up to 1 month after last dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tmax, ss
Time Frame: Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose
|
Time of maximum observed concentration; safety and validity criteria
|
Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose
|
Cmax, ss
Time Frame: Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose
|
Maximum observed concentration; safety and validity criteria
|
Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose
|
Cmin, ss
Time Frame: Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose
|
Minimum observed concentration; safety and validity criteria
|
Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose
|
t1/2, ss
Time Frame: Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose
|
Elimination half-life; safety and validity criteria
|
Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose
|
AUC0-24, ss
Time Frame: Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose
|
Area under the concentration-time curve (AUC) from time 0 to 24 hours; safety and validity criteria
|
Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose
|
AUC0-72, ss
Time Frame: Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose
|
Area under the concentration-time curve (AUC) from time 0 to 72 hours; safety and validity criteria
|
Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose
|
AUC0-∞, ss
Time Frame: Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose
|
Area under the concentration-time curve (AUC) from time 0 to infinity; safety and validity criteria
|
Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose
|
CL/F ss
Time Frame: Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose
|
Apparent clearance; safety and validity criteria
|
Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose
|
DF
Time Frame: Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose
|
Degree of fluctuation; safety and validity criteria
|
Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Yanhua Ding, MD, Phase I Clinical Trial Unit, The First Hospital of Jilin University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 19, 2018
Primary Completion (Actual)
December 25, 2018
Study Completion (Actual)
December 25, 2018
Study Registration Dates
First Submitted
November 2, 2018
First Submitted That Met QC Criteria
November 19, 2018
First Posted (Actual)
November 21, 2018
Study Record Updates
Last Update Posted (Actual)
August 13, 2019
Last Update Submitted That Met QC Criteria
August 12, 2019
Last Verified
August 1, 2019
More Information
Terms related to this study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Interactions
-
Sunnybrook Health Sciences CentreUniversity Health Network, TorontoCompletedDrug Drug Interactions | Critical Laboratory Values | Drug Laboratory InteractionsCanada
-
Qure Healthcare, LLCAegis Sciences CorporationCompleted
-
Sumitomo Pharma America, Inc.CompletedDrug-drug InteractionsUnited States
-
Muğla Sıtkı Koçman UniversityUnknownPolypharmacy | Drug-drug InteractionsTurkey
-
CTI BioPharmaPPDCompletedDrug InteractionsUnited States
-
Seoul National University Bundang HospitalEnrolling by invitationDrug InteractionsKorea, Republic of
-
Gerd MikusCompleted
-
Vertex Pharmaceuticals IncorporatedCompletedDrug InteractionsUnited States
-
AbbottCompleted
Clinical Trials on SH229
-
Nanjing Sanhome Pharmaceutical, Co., Ltd.Completed
-
Nanjing Sanhome Pharmaceutical, Co., Ltd.Unknown